{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:23:00Z","timestamp":1791559380344,"version":"4.3.4"},"reference-count":5,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Immune-related adverse events (irAEs) are well-documented cutaneous toxicities associated with immune checkpoint inhibitors. They typically emerge within the first 3 months of therapy; however, delayed presentations may occur even after treatment cessation. We report a case of late-onset lichenoid dermatitis developing several months following discontinuation of anti-programmed cell death 1 therapy. Histopathological findings and clinical correlation supported the diagnosis. This case highlights the potential for post-therapy cutaneous irAEs and underscores the importance of long-term dermatological surveillance in patients treated with immune checkpoint inhibitors.<\/jats:p>","DOI":"10.1093\/skinhd\/vzag052","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T12:15:14Z","timestamp":1773404114000},"page":"586-588","source":"Crossref","is-referenced-by-count":1,"title":["Delayed lichenoid immune-related adverse event after nivolumab discontinuation"],"prefix":"10.1093","volume":"6","author":[{"given":"Micaela","family":"Guglielmetti-Macchiavello","sequence":"first","affiliation":[{"name":"Medical Skin Center , Vi\u00f1a del Mar ,","place":["Chile"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia","family":"Poggi","sequence":"additional","affiliation":[{"name":"Laboratorio de Patolog\u00eda de Precisi\u00f3n, Universidad de Valpara\u00edso , Valpara\u00edso ,","place":["Chile"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Guglielmetti-Valenzuela","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Universidad de Valpara\u00edso , Valpara\u00edso ,","place":["Chile"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7435-7868","authenticated-orcid":false,"given":"Eduardo","family":"Rozas-Mu\u00f1oz","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital San Pablo , Coquimbo ,","place":["Chile"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"key":"2026073105081622800_vzag052-B1","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.jaad.2019.06.035","article-title":"Survival and prognosis of individuals receiving programmed cell death 1 inhibitor with and without immunologic cutaneous adverse events","volume":"82","author":"Chan","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2026073105081622800_vzag052-B2","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.jaad.2020.03.132","article-title":"Immune checkpoint inhibitor-related dermatologic adverse events","volume":"83","author":"Geisler","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2026073105081622800_vzag052-B3","doi-asserted-by":"crossref","first-page":"e007667","DOI":"10.1136\/jitc-2023-007675","article-title":"Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy","volume":"12","author":"Chen","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2026073105081622800_vzag052-B4","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/DAD.0000000000000688","article-title":"Lichenoid dermatologic toxicity from immune checkpoint blockade therapy: a detailed examination of the clinicopathologic features","volume":"39","author":"Tetzlaff","year":"2017","journal-title":"Am J Dermatopathol"},{"key":"2026073105081622800_vzag052-B5","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1001\/jamadermatol.2018.1912","article-title":"Timing of onset of adverse cutaneous reactions associated with programmed cell death protein 1 inhibitor therapy","volume":"154","author":"Wang","year":"2018","journal-title":"JAMA Dermatol"}],"container-title":["Skin Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/skinhd\/article-pdf\/6\/4\/586\/68207652\/vzag052.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/skinhd\/article-pdf\/6\/4\/586\/68207652\/vzag052.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T09:08:25Z","timestamp":1785488905000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/skinhd\/article\/6\/4\/586\/8666942"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,4]]},"references-count":5,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,5,4]]},"published-print":{"date-parts":[[2026,7,31]]}},"URL":"https:\/\/doi.org\/10.1093\/skinhd\/vzag052","relation":{},"ISSN":["2690-442X"],"issn-type":[{"value":"2690-442X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,5,4]]}}}